Factors Favouring the Development of Clostridium Difficile Infection in Critically Ill Patients

1. Walters PR, Zuckerbraun BS. Clostridium difficile infection. Clinical Challenges and management strategies. Critical Care Nurse. 2014;34:2-35.Search in Google Scholar

2. Barletta JF, Sclar DA. Proton pump inhibitors increase the risk for hospital-acquired Clostridium difficile infection in critically ill patients. Crit Care. 2014;18:714.10.1186/s13054-014-0714-7429382625540023Search in Google Scholar

3. Vindigni SM, Surawicz CM. C. difficile Infection: Changing epidemiology and management paradigms. Clin Transl Gastroenterol. 2015;6,e99 .Search in Google Scholar

4. Miller BA, Chen LF, Sexton DJ, Anderson DJ. Comparison of the burdens of hospital onset, healthcare facility-associated Clostridium difficile infection and of healthcare-associated infection due to methicillin-resistant Staphylococcus aureus in community hospitals. Infect Control Hosp Epidemiol. 2011;32:387-90.10.1086/65915621460491Search in Google Scholar

5. Vaishnavi C. Clinical spectrum & pathogenesis of Clostridium difficile associated diseases. Indian J Med Res. 2010; 131:487-99.Search in Google Scholar

6. McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin gene variant strain of Clostridium difficile. N Engl J Med. 2005;353:2433-41.10.1056/NEJMoa05159016322603Search in Google Scholar

7. Vecchio AL, Zacur GM. Clostridium difficile infection: an update on epidemiology, risk factors, and therapeutic options. Curr Opin Gastroenterol. 2012;28:1-9.10.1097/MOG.0b013e32834bc9a922134217Search in Google Scholar

8. Biswal S. Proton pump inhibitors and risk for Clostridium difficile associated diarrhea. Biomed J. 2014;37:178-83.10.4103/2319-4170.12800225116712Search in Google Scholar

9. Oake N, Taljaard M, Walraven C, Wilson K, Roth V, Forster AJ. The effect of hospital-acquired Clostridium difficile infection on in-hospital mortality. Arch Intern Med. 2010;170:1804-10.10.1001/archinternmed.2010.40521059973Search in Google Scholar

10. Poutanen SM, Simor AE. Clostridium difficile associated diarrhea in adults. CMAJ. 2004;171:51-8.10.1503/cmaj.103118943768615238498Search in Google Scholar

11. Voth DE, Ballard JD. Clostridium difficile toxins: Mechanisms of action and role in disease. Clin Microbiol Rev. 2005;18:247-63.10.1128/CMR.18.2.247-263.2005108279915831824Search in Google Scholar

12. Donskey CJ. The role of the intestinal tract as a reservoir and source for transmission of nosocomial pathogens. Clin Infect Dis. 2004;39:219-26.10.1086/42200215307031Search in Google Scholar

13. Pepin J, Saheb N, Coulombe MA, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: A cohort study during an epidemic in Quebec. Clin Infect Dis. 2005;41:1254-60.10.1086/49698616206099Search in Google Scholar

14. Neal KR, Scott HM, Slack RCB, Logan RFA. Omeprazole as a risk factor for campylobacter gastroenteritis: case control study. BMJ 1996;321:414-5.10.1136/bmj.312.7028.414Search in Google Scholar

15. Williams C. Occurrence and significance of gastric colonization during acid-inhibitory therapy. Best Pract Res Clin Gastroenterol. 2001;15:511-21.10.1053/bega.2001.0191Search in Google Scholar

16. Linsky A, Gupta K, Lawler EV, Fonda JR, Hermos JA. Proton pump inhibitors and risk for recurrent Clostridium difficile infection. Arch Intern Med. 2010;170:772-8.10.1001/archinternmed.2010.73Search in Google Scholar

17. Klingensmith ME, Neville LL, Delpire E, Wolfe MM, Soybel DI. Gastrin-mediated effects of omeprazole on rat colon mucosa. Surgery. 1999;126:272-8.10.1016/S0039-6060(99)70165-0Search in Google Scholar

18. Liebensten Z, Wenisch C, Patruta S, Parschalk B, Daxbock F, Garninger W. Omeprazole treatment diminishes intra- and extra-cellular neutrophil reactive oxygen production and bacterial activity. Crit Care Med. 2002;30:1118-22.10.1097/00003246-200205000-0002612006811Search in Google Scholar

19. Dial S, Delaney JAC, Barkun AN, Suissa S. Use of gastric acid-suppressive agents and the risk of communityacquired Clostridium difficile-associated disease. JAMA. 2005;294:2989-95.10.1001/jama.294.23.298916414946Search in Google Scholar

20. MacLaren R, Reynolds PM, Allen RR. Histamine-2 Receptor Antagonists vs Proton Pump Inhibitors on Gastrointestinal Tract Hemmorhage and Infectious Complications in the Intensive Care Unit FREE. JAMA Intern Med. 2014;174:564-74.10.1001/jamainternmed.2013.1467324535015Search in Google Scholar

21. Dubberke ER, Reske KA, Yan Y, Olsen MA, MacDonald LC, Fraser VJ. Clostridium difficile-associated disease in a setting of endemicity: identification of novel risk factors. Clin Infect Dis. 2007;45:1543-9.10.1086/52358218190314Search in Google Scholar